Anti-viral developer Alios raises $8M more for $32M
Alios BioPharma, developer of anti-viral therapies, has tacked $8 million onto its first round of funding, bringing its total to $32 million. The new money came solely from SR One. Based in South San Francisco, the company plans to use the money to push its lead compound past phase-one trials.
Alios brought in the initial $24 million from Novartis Ventures, Novo AS and Roche Venture Fund.
Next Story: HP funds 60 researchers at 46 universities
Previous Story: Analog is dead! Long live digital TV!
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.